Kezar Life Sciences Q2 net loss $24.3M; cash $236.6M; clinical trials advancing

Kezar Life Sciences, Inc.

2023-Q2 EPS reported -$0.64

Net loss of $24.3M ($0.34 per share) vs $16.2M ($0.25) in Q2 2022.
Cash equivalents and marketable securities $236.6M at June 30, 2023, down from $276.6M at Dec 31, 2022.
R&D expenses rose to $21.0M from $11.3M year-over-year, driven by zetomipzomib and KZR-261 programs.
PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) open for enrollment; KZR-261 dose escalation continues.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kezar Life Sciences, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Kezar Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.